Enanta Pharmaceuticals’ (ENTA) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a report released on Friday morning,Benzinga reports. They currently have a $20.00 price objective on the biotechnology company’s stock.

Several other analysts have also issued reports on the company. Jefferies Financial Group raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the stock from $14.00 to $20.00 in a report on Wednesday, October 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 8th. Evercore ISI decreased their target price on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating on the stock in a report on Monday, September 15th. Westpark Capital upped their price target on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, September 30th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Enanta Pharmaceuticals in a research note on Friday, November 14th. They issued an “overweight” rating and a $17.00 price objective on the stock. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $20.33.

Enanta Pharmaceuticals Trading Down 2.5%

Shares of ENTA opened at $13.11 on Friday. Enanta Pharmaceuticals has a 12 month low of $4.09 and a 12 month high of $17.15. The firm’s 50 day moving average is $13.81 and its 200-day moving average is $10.51. The stock has a market capitalization of $378.35 million, a PE ratio of -3.42 and a beta of 0.95.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.26. Enanta Pharmaceuticals had a negative return on equity of 93.76% and a negative net margin of 125.36%.The business had revenue of $15.13 million during the quarter, compared to analysts’ expectations of $15.60 million. Equities research analysts predict that Enanta Pharmaceuticals will post -4.65 earnings per share for the current fiscal year.

Insider Activity at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, insider Yat Sun Or sold 2,390 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $34,009.70. Following the sale, the insider owned 371,392 shares in the company, valued at $5,284,908.16. This trade represents a 0.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Tara Lynn Kieffer sold 2,106 shares of the business’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $14.23, for a total transaction of $29,968.38. Following the sale, the insider directly owned 30,620 shares in the company, valued at approximately $435,722.60. The trade was a 6.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 11,961 shares of company stock valued at $170,149 in the last quarter. Insiders own 13.89% of the company’s stock.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Farther Finance Advisors LLC boosted its stake in shares of Enanta Pharmaceuticals by 11,558.0% during the second quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 5,779 shares in the last quarter. Quarry LP bought a new position in Enanta Pharmaceuticals in the 3rd quarter valued at approximately $81,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Enanta Pharmaceuticals during the 2nd quarter worth approximately $88,000. China Universal Asset Management Co. Ltd. grew its holdings in Enanta Pharmaceuticals by 103.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,747 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 4,454 shares during the last quarter. Finally, AlphaQuest LLC increased its position in Enanta Pharmaceuticals by 18.1% in the 3rd quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 1,562 shares during the period. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.